Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism

NCT02234843 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02234843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02234843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
November 13, 2014
Completion date
January 30, 2019
Enrollment
500 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism